Elutia, Inc. Stock Plummets to New 52-Week Low of $0.98

Elutia, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 0.98 on September 25, 2025. This significant decline marks a stark contrast to its 52-week high of USD 5.12, reflecting a challenging year for the company, which has seen its stock price plummet by 70.32% over the past year. The company's market capitalization stands at approximately USD 80 million, and it currently operates without a dividend yield. Elutia's financial metrics indicate a negative book value, with a debt-to-equity ratio of -0.62, suggesting difficulties in managing its liabilities. The company has reported a decline in net sales at an annual rate of -16.74% and an operating profit decrease of -18.21% over the last five years. Recent financial results show concerning figures, including an operating cash flow of USD -32.8 million and a pre-tax profit of USD -7.83 million. With a return on equity of 67.24%, Elutia's performance remains under scrutiny as it continues to navigate a challenging market landscape.